Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy.

Future oncology (London, England)

Mahoney DJ, Stojdl DF.
PMID: 22409457
Future Oncol. 2012 Mar;8(3):219-21. doi: 10.2217/fon.12.2.

No abstract available.

Cite
Mahoney DJ, Stojdl DF. Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy. Future Oncol. 2012;8(3):219-21doi: 10.2217/fon.12.2.
Mahoney, D. J., & Stojdl, D. F. (2012). Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy. Future oncology (London, England), 8(3), 219-21. https://doi.org/10.2217/fon.12.2
Mahoney, Douglas J, and Stojdl, David F. "Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy." Future oncology (London, England) vol. 8,3 (2012): 219-21. doi: https://doi.org/10.2217/fon.12.2
Mahoney DJ, Stojdl DF. Fighting fire with fire: rewiring tumor cells for oncolytic virotherapy. Future Oncol. 2012 Mar;8(3):219-21. doi: 10.2217/fon.12.2. PMID: 22409457.
Copy Download .nbib Format: NLM
Achieving systemic delivery of oncolytic viruses.

Expert opinion on drug delivery

Hill C, Carlisle R.
PMID: 31144549
Expert Opin Drug Deliv. 2019 Jun;16(6):607-620. doi: 10.1080/17425247.2019.1617269. Epub 2019 May 30.

AREAS COVERED: This review catalogs the techniques used to enhance OV delivery. Firstly, insights from clinical trials of OV provide evidence of the need for enhanced delivery strategies. Secondly, the techniques applied to overcome the challenges highlighted by clinical...

Cite
Hill C, Carlisle R. Achieving systemic delivery of oncolytic viruses. Expert Opin Drug Deliv. 2019;16(6):607-620doi: 10.1080/17425247.2019.1617269.
Hill, C., & Carlisle, R. (2019). Achieving systemic delivery of oncolytic viruses. Expert opinion on drug delivery, 16(6), 607-620. https://doi.org/10.1080/17425247.2019.1617269
Hill, Claudia, and Carlisle, Robert. "Achieving systemic delivery of oncolytic viruses." Expert opinion on drug delivery vol. 16,6 (2019): 607-620. doi: https://doi.org/10.1080/17425247.2019.1617269
Hill C, Carlisle R. Achieving systemic delivery of oncolytic viruses. Expert Opin Drug Deliv. 2019 Jun;16(6):607-620. doi: 10.1080/17425247.2019.1617269. Epub 2019 May 30. PMID: 31144549.
Copy Download .nbib Format: NLM
Redemption for the field of oncolytic virotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy

Kirn DH.
PMID: 21455205
Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45.

No abstract available.

Cite
Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther. 2011;19(4):627-8doi: 10.1038/mt.2011.45.
Kirn, D. H. (2011). Redemption for the field of oncolytic virotherapy. Molecular therapy : the journal of the American Society of Gene Therapy, 19(4), 627-8. https://doi.org/10.1038/mt.2011.45
Kirn, David H. "Redemption for the field of oncolytic virotherapy." Molecular therapy : the journal of the American Society of Gene Therapy vol. 19,4 (2011): 627-8. doi: https://doi.org/10.1038/mt.2011.45
Kirn DH. Redemption for the field of oncolytic virotherapy. Mol Ther. 2011 Apr;19(4):627-8. doi: 10.1038/mt.2011.45. PMID: 21455205; PMCID: PMC3070109.
Copy Download .nbib Format: NLM
Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword.

Cytokine & growth factor reviews

Bell J, Kirn D.
PMID: 20444639
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2):83-4. doi: 10.1016/j.cytogfr.2010.04.004. Epub 2010 May 04.

No abstract available.

Cite
Bell J, Kirn D. Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword. Cytokine Growth Factor Rev. 2010;21(2):83-4doi: 10.1016/j.cytogfr.2010.04.004.
Bell, J., & Kirn, D. (2010). Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword. Cytokine & growth factor reviews, 21(2), 83-4. https://doi.org/10.1016/j.cytogfr.2010.04.004
Bell, John, and Kirn, David. "Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword." Cytokine & growth factor reviews vol. 21,2 (2010): 83-4. doi: https://doi.org/10.1016/j.cytogfr.2010.04.004
Bell J, Kirn D. Recent advances in the development of oncolytic viruses as cancer therapeutics. Foreword. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2):83-4. doi: 10.1016/j.cytogfr.2010.04.004. Epub 2010 May 04. PMID: 20444639.
Copy Download .nbib Format: NLM
The emerging role of oncolytic virus therapy against cancer.

Chinese clinical oncology

Russell L, Peng KW.
PMID: 29764161
Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04.

This review discusses current clinical advancements in oncolytic viral therapy, with a focus on the viral platforms approved for clinical use and highlights the benefits each platform provides. Three oncolytic viruses (OVs), an echovirus, an adenovirus, and a herpes...

Cite
Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol. 2018;7(2):16doi: 10.21037/cco.2018.04.04.
Russell, L., & Peng, K. W. (2018). The emerging role of oncolytic virus therapy against cancer. Chinese clinical oncology, 7(2), 16. https://doi.org/10.21037/cco.2018.04.04
Russell, Luke, and Peng, Kah-Whye. "The emerging role of oncolytic virus therapy against cancer." Chinese clinical oncology vol. 7,2 (2018): 16. doi: https://doi.org/10.21037/cco.2018.04.04
Russell L, Peng KW. The emerging role of oncolytic virus therapy against cancer. Chin Clin Oncol. 2018 Apr;7(2):16. doi: 10.21037/cco.2018.04.04. PMID: 29764161; PMCID: PMC6557159.
Copy Download .nbib Format: NLM
Reovirus: viral therapy for cancer 'as nature intended'.

Clinical oncology (Royal College of Radiologists (Great Britain))

Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H.
PMID: 18583112
Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25.

Oncolytic viruses are tumour selective and able to lyse cancer cells after infection. Reovirus is an example of a wild-type oncolytic virus and is currently being investigated as a potential novel therapy for cancer. This overview gives a brief...

Cite
Comins C, Heinemann L, Harrington K, et al. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008;20(7):548-54doi: 10.1016/j.clon.2008.04.018.
Comins, C., Heinemann, L., Harrington, K., Melcher, A., De Bono, J., & Pandha, H. (2008). Reovirus: viral therapy for cancer 'as nature intended'. Clinical oncology (Royal College of Radiologists (Great Britain)), 20(7), 548-54. https://doi.org/10.1016/j.clon.2008.04.018
Comins, C, et al. "Reovirus: viral therapy for cancer 'as nature intended'." Clinical oncology (Royal College of Radiologists (Great Britain)) vol. 20,7 (2008): 548-54. doi: https://doi.org/10.1016/j.clon.2008.04.018
Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):548-54. doi: 10.1016/j.clon.2008.04.018. Epub 2008 Jun 25. PMID: 18583112.
Copy Download .nbib Format: NLM
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Cytokine & growth factor reviews

Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH.
PMID: 20472490
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2):85-9. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15.

Chemotherapy remains a common mode of anticancer treatment even though in most cancer indications the therapeutic approach is not effective and ultimately associated with the onset of chemoresistance. A better understanding of genetic differences in tumors ushered in the...

Cite
Breitbach CJ, Reid T, Burke J, et al. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010;21(2):85-9doi: 10.1016/j.cytogfr.2010.02.001.
Breitbach, C. J., Reid, T., Burke, J., Bell, J. C., & Kirn, D. H. (2010). Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine & growth factor reviews, 21(2), 85-9. https://doi.org/10.1016/j.cytogfr.2010.02.001
Breitbach, Caroline J, et al. "Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval." Cytokine & growth factor reviews vol. 21,2 (2010): 85-9. doi: https://doi.org/10.1016/j.cytogfr.2010.02.001
Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2):85-9. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15. PMID: 20472490.
Copy Download .nbib Format: NLM
Personalized virotherapy in cancer.

Aging

Cafferata EG, Podhajcer OL.
PMID: 26022702
Aging (Albany NY). 2015 May;7(5):288-9. doi: 10.18632/aging.100750.

No abstract available.

Cite
Cafferata EG, Podhajcer OL. Personalized virotherapy in cancer. Aging (Albany NY). 2015;7(5):288-9doi: 10.18632/aging.100750.
Cafferata, E. G., & Podhajcer, O. L. (2015). Personalized virotherapy in cancer. Aging, 7(5), 288-9. https://doi.org/10.18632/aging.100750
Cafferata, Eduardo G, and Podhajcer, Osvaldo L. "Personalized virotherapy in cancer." Aging vol. 7,5 (2015): 288-9. doi: https://doi.org/10.18632/aging.100750
Cafferata EG, Podhajcer OL. Personalized virotherapy in cancer. Aging (Albany NY). 2015 May;7(5):288-9. doi: 10.18632/aging.100750. PMID: 26022702; PMCID: PMC4468308.
Copy Download .nbib Format: NLM
Oncolytic viruses from the perspective of the immune system.

Future microbiology

Alemany R, Cascallo M.
PMID: 19492964
Future Microbiol. 2009 Jun;4(5):527-36. doi: 10.2217/fmb.09.28.

Cancer treatment with oncolytic viruses is at a crucial intersection from where two very different routes can be taken. The key role of the immune system needs to be addressed proactively to succeed. An immunocentric point of view posits...

Cite
Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol. 2009;4(5):527-36doi: 10.2217/fmb.09.28.
Alemany, R., & Cascallo, M. (2009). Oncolytic viruses from the perspective of the immune system. Future microbiology, 4(5), 527-36. https://doi.org/10.2217/fmb.09.28
Alemany, Ramon, and Cascallo, Manel. "Oncolytic viruses from the perspective of the immune system." Future microbiology vol. 4,5 (2009): 527-36. doi: https://doi.org/10.2217/fmb.09.28
Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol. 2009 Jun;4(5):527-36. doi: 10.2217/fmb.09.28. PMID: 19492964.
Copy Download .nbib Format: NLM
Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Cancer gene therapy

Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J.
PMID: 30177818
Cancer Gene Ther. 2019 Mar;26(3):59-73. doi: 10.1038/s41417-018-0042-1. Epub 2018 Sep 04.

The 11th International Oncolytic Virus Conference (IOVC) was held from April 9-12, 2018 in Oxford, UK. This is part of the high-profile academic-led series of meetings that was started back in 2002 by Steve Russell and John Bell, with...

Cite
Dyer A, Baugh R, Chia SL, et al. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 2018;26(3):59-73doi: 10.1038/s41417-018-0042-1.
Dyer, A., Baugh, R., Chia, S. L., Frost, S., Iris, Jacobus, E. J., Khalique, H., Pokrovska, T. D., Scott, E. M., Taverner, W. K., Seymour, L. W., & Lei, J. (2019). Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer gene therapy, 26(3), 59-73. https://doi.org/10.1038/s41417-018-0042-1
Dyer, Arthur, et al. "Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference." Cancer gene therapy vol. 26,3 (2019): 59-73. doi: https://doi.org/10.1038/s41417-018-0042-1
Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J. Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Ther. 2019 Mar;26(3):59-73. doi: 10.1038/s41417-018-0042-1. Epub 2018 Sep 04. PMID: 30177818.
Copy Download .nbib Format: NLM
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.

Viruses

Rajani KR, Vile RG.
PMID: 26580645
Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914.

Oncolytic viruses represent a diverse class of replication competent viruses that curtail tumor growth. These viruses, through their natural ability or through genetic modifications, can selectively replicate within tumor cells and induce cell death while leaving normal cells intact....

Cite
Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses. 2015;7(11):5889-901doi: 10.3390/v7112914.
Rajani, K. R., & Vile, R. G. (2015). Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses, 7(11), 5889-901. https://doi.org/10.3390/v7112914
Rajani, Karishma R, and Vile, Richard G. "Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors." Viruses vol. 7,11 (2015): 5889-901. doi: https://doi.org/10.3390/v7112914
Rajani KR, Vile RG. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses. 2015 Nov 13;7(11):5889-901. doi: 10.3390/v7112914. PMID: 26580645; PMCID: PMC4664987.
Copy Download .nbib Format: NLM
Current strategies of virotherapy in clinical trials for cancer treatment.

Journal of medical virology

Lin W, Zhao Y, Zhong L.
PMID: 33738818
J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23.

As a novel immune-active agent for cancer treatment, viruses have the ability of infecting and replicating in tumor cells. The safety and efficacy of viruses has been tested and confirmed in preclinical and clinical trials. In the last decade,...

Cite
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021;93(8):4668-4692doi: 10.1002/jmv.26947.
Lin, W., Zhao, Y., & Zhong, L. (2021). Current strategies of virotherapy in clinical trials for cancer treatment. Journal of medical virology, 93(8), 4668-4692. https://doi.org/10.1002/jmv.26947
Lin, Weijian, et al. "Current strategies of virotherapy in clinical trials for cancer treatment." Journal of medical virology vol. 93,8 (2021): 4668-4692. doi: https://doi.org/10.1002/jmv.26947
Lin W, Zhao Y, Zhong L. Current strategies of virotherapy in clinical trials for cancer treatment. J Med Virol. 2021 Aug;93(8):4668-4692. doi: 10.1002/jmv.26947. Epub 2021 Apr 23. PMID: 33738818.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries